Search Results

There are 18356 results for: content related to: Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors

  1. Enzyme- and Transporter-Mediated Drug Interactions with Small Molecule Tyrosine Kinase Inhibitors

    Journal of Pharmaceutical Sciences

    Volume 103, Issue 12, December 2014, Pages: 3810–3833, Jie Shao, John S. Markowitz, Di Bei and Guohua An

    Version of Record online : 10 OCT 2014, DOI: 10.1002/jps.24113

  2. You have full text access to this OnlineOpen article
    Metabolism-related pharmacokinetic drug−drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations

    British Journal of Clinical Pharmacology

    Volume 79, Issue 2, February 2015, Pages: 241–253, Yi Ling Teo, Han Kiat Ho and Alexandre Chan

    Version of Record online : 20 JAN 2015, DOI: 10.1111/bcp.12496

  3. You have full text access to this Open Access content
    Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

    Journal of Cellular and Molecular Medicine

    Volume 14, Issue 1-2, January-February 2010, Pages: 51–69, Luis Paz-Ares, Denis Soulières, Ivan Melezínek, Joachim Moecks, Lorenz Keil, Tony Mok, Rafael Rosell and Barbara Klughammer

    Version of Record online : 8 DEC 2009, DOI: 10.1111/j.1582-4934.2009.00991.x

  4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer

    Intervention Review

    The Cochrane Library

    Janette Greenhalgh, Kerry Dwan, Angela Boland, Victoria Bates, Fabio Vecchio, Yenal Dundar, Pooja Jain and John A Green

    Published Online : 25 MAY 2016, DOI: 10.1002/14651858.CD010383.pub2

  5. Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR-Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway

    ChemMedChem

    Volume 7, Issue 4, April 2012, Pages: 650–662, Dr. Anne Pick and Prof. Dr. Michael Wiese

    Version of Record online : 22 FEB 2012, DOI: 10.1002/cmdc.201100543

  6. You have free access to this content
    Retracted: Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines

    Cancer

    Volume 115, Issue 10, 15 May 2009, Pages: 2165–2176, Shirish M. Gadgeel, Shadan Ali, Philip A. Philip, Antoinette Wozniak and Fazlul H. Sarkar

    Version of Record online : 13 MAR 2009, DOI: 10.1002/cncr.24250

    Corrected by:

    Information Item: Retraction

    Vol. 122, Issue 20, 3248, Version of Record online: 29 JUL 2016

  7. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry

    Biomedical Chromatography

    Volume 27, Issue 4, April 2013, Pages: 466–476, N. A. G. Lankheet, M. J. X. Hillebrand, H. Rosing, J. H. M. Schellens, J. H. Beijnen and A. D. R. Huitema

    Version of Record online : 17 SEP 2012, DOI: 10.1002/bmc.2814

  8. Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

    Journal of Cellular Physiology

    Volume 205, Issue 3, December 2005, Pages: 355–363, Massimo Di Maio, Cesare Gridelli, Nicola Normanno, Francesco Perrone and Fortunato Ciardiello

    Version of Record online : 13 MAY 2005, DOI: 10.1002/jcp.20402

  9. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma

    The Journal of Pathology

    Volume 234, Issue 2, October 2014, Pages: 277–288, Kaito Nihira, Yasuhiro Miki, Shinya Iida, Sodai Narumi, Katsuhiko Ono, Erina Iwabuchi, Kazue Ise, Kazushige Mori, Mikiyoshi Saito, Masahito Ebina, Ikuro Sato, Makoto Maemondo, Hisafumi Yamada-Okabe, Takashi Kondo and Hironobu Sasano

    Version of Record online : 18 AUG 2014, DOI: 10.1002/path.4354

  10. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux

    Biopharmaceutics & Drug Disposition

    Volume 37, Issue 7, October 2016, Pages: 397–408, Ronilda D'Cunha, SoHyun Bae, Daryl J. Murry and Guohua An

    Version of Record online : 13 SEP 2016, DOI: 10.1002/bdd.2022

  11. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

    Journal of Cellular Physiology

    Volume 226, Issue 9, September 2011, Pages: 2316–2328, Mary E. Irwin, Kelly L. Mueller, Natacha Bohin, Yubin Ge and Julie L. Boerner

    Version of Record online : 9 JUN 2011, DOI: 10.1002/jcp.22570

  12. You have full text access to this OnlineOpen article
    Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC

    Journal of Cellular and Molecular Medicine

    Volume 18, Issue 8, August 2014, Pages: 1519–1539, Luis Paz-Ares, Denis Soulières, Joachim Moecks, Ilze Bara, Tony Mok and Barbara Klughammer

    Version of Record online : 6 AUG 2014, DOI: 10.1111/jcmm.12278

  13. You have free access to this content
    Retracted: Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

    Cancer

    Volume 110, Issue 12, 15 December 2007, Pages: 2775–2784, Shirish M. Gadgeel, Shadan Ali, Philip A. Philip, Fakhara Ahmed, Antoinette Wozniak and Fazlul H. Sarkar

    Version of Record online : 19 OCT 2007, DOI: 10.1002/cncr.23100

    Corrected by:

    Information Item: Retraction

    Vol. 122, Issue 20, 3248, Version of Record online: 29 JUL 2016

  14. You have free access to this content
    A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

    British Journal of Clinical Pharmacology

    Volume 76, Issue 3, September 2013, Pages: 396–411, Rashmi R. Shah, Samantha A. Roberts and Devron R. Shah

    Version of Record online : 20 AUG 2013, DOI: 10.1111/bcp.12085

  15. You have free access to this content
    EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors

    The FEBS Journal

    Volume 277, Issue 2, January 2010, Pages: 316–326, Kenji Takeuchi and Fumiaki Ito

    Version of Record online : 18 NOV 2009, DOI: 10.1111/j.1742-4658.2009.07450.x

  16. You have free access to this content
    Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring

    American Journal of Hematology

    Volume 91, Issue 2, February 2016, Pages: 252–265, Elias Jabbour and Hagop Kantarjian

    Version of Record online : 22 JAN 2016, DOI: 10.1002/ajh.24275

  17. Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells

    Molecular Carcinogenesis

    Volume 55, Issue 5, May 2016, Pages: 991–1001, Yongik Lee, Yian Wang, Michael James, Joseph H. Jeong and Ming You

    Version of Record online : 4 JUN 2015, DOI: 10.1002/mc.22342

  18. You have full text access to this OnlineOpen article
    Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells

    Cancer Science

    Volume 107, Issue 4, April 2016, Pages: 444–451, Keizo Misumi, Jiying Sun, Aiko Kinomura, Yoshihiro Miyata, Morihito Okada and Satoshi Tashiro

    Version of Record online : 16 MAR 2016, DOI: 10.1111/cas.12899

  19. You have full text access to this Open Access content
    Gefitinib versus erlotinib as salvage treatment for lung adenocarcinoma patients who benefited from the initial gefitinib: A retrospective study

    Thoracic Cancer

    Volume 4, Issue 2, May 2013, Pages: 109–116, Shufei Yu, Yan Wang, Junling Li, Xuezhi Hao, Bin Wang, Ziping Wang, Xiangru Zhang and Yuankai Shi

    Version of Record online : 22 APR 2013, DOI: 10.1111/j.1759-7714.2012.00152.x

  20. You have full text access to this OnlineOpen article
    Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

    Cancer Medicine

    Volume 4, Issue 11, November 2015, Pages: 1621–1632, Robert M. Jotte and David R. Spigel

    Version of Record online : 26 AUG 2015, DOI: 10.1002/cam4.506